LANTERN PHARMA INC (LTRN) Stock Income Statement
USA - NASDAQ:LTRN - US51654W1018 - Common Stock
3.48 USD
-0.06 (-1.69%)
3.79 USD
+0.31 (+8.91%)
| TTM (2025-6-30) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | |||
| Gross Premiums Earned | null | null | null | null | null | |||
| Loss Claims | null | null | null | null | null | |||
| Deferred Policy Acquisition Expense | null | null | null | null | null | |||
| Net Interest Income | null | null | null | null | null | |||
| Non Interest Income | null | null | null | null | null | |||
| Loan Loss Provision | null | null | null | null | null | |||
| Net Interest Income after Provision | null | null | null | null | null | |||
| Non Interest Expense | null | null | null | null | null | |||
| Minority Interest Expense | null | null | null | null | null | |||
| Cost Of Goods | null | null | null | null | null | |||
| Gross Profit | null | null | null | null | null | |||
| Operating Expenses | 20.50M | 22.22M | 17.88M | 14.43M | 12.59M | |||
| Research and Development | 14.32M | 16.13M | 11.89M | 8.60M | 7.57M | |||
| Selling, General, and Administrative Expenses | 6.18M | 6.09M | 5.98M | 5.83M | 5.02M | |||
| Operating Income | -20.50M | -22.22M | -17.88M | -14.43M | -12.59M | |||
| Interest Income/Expense | 617.40K | 742.40K | 765.40K | 200.00K | 120.00K | |||
| Other Income/Expense | 635.90K | 692.90K | 1.15M | -30.00K | null | |||
| Non Recurring Items | null | null | null | null | 110.00K | |||
| Income Before Taxes | -19.25M | -20.78M | -15.96M | -14.26M | -12.36M | |||
| Income Tax | null | null | null | null | null | |||
| Net Income | -19.25M | -20.78M | -15.96M | -14.26M | -12.36M | |||
| EBITDA | -20.48M | -22.20M | -17.86M | -14.42M | -12.58M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -1.7857 | -1.9309 | -1.4722 | -1.31 | -1.13 | |||
| Non GAAP EPS | -1.78 | -1.93 | -1.48 | -1.31 | -1.13 | |||
| Statistics | ||||||||
All data in USD